18. Immune Tolerance Induction Programs

  1. Emérito-Carlos Rodríguez-Merchán MD, PHD3,4 and
  2. Leonard A. Valentino MD5
  1. Jan Blatny MD, PhD1 and
  2. Prasad Mathew MB, BS, DCH, FAAP2

Published Online: 12 MAY 2011

DOI: 10.1002/9781119979401.ch18

Current and Future Issues in Hemophilia Care

Current and Future Issues in Hemophilia Care

How to Cite

Blatny, J. and Mathew, P. (2011) Immune Tolerance Induction Programs, in Current and Future Issues in Hemophilia Care (eds E.-C. Rodríguez-Merchán and L. A. Valentino), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119979401.ch18

Editor Information

  1. 3

    Department of Orthopedic Surgery and Hemophilia Unit, La Paz University Hospital, Spain

  2. 4

    School of Medicine, Autonomous University, Madrid, Spain

  3. 5

    Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Author Information

  1. 1

    Children's University Hospital Brno, Brno, Czech Republic

  2. 2

    University of New Mexico, Albuquerque, NM, USA

Publication History

  1. Published Online: 12 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470670576

Online ISBN: 9781119979401



  • hemophilia;
  • inhibitors;
  • immune tolerance;
  • bypassing agents;
  • Bethesda units


Inhibitor development is currently one of the most serious complications in the management of patients with hemophilia. Tolerizing patients with inhibitors so as to make substitution therapy with regular factor VIII or IX concentrates possible again, is the goal of immune tolerance induction. Several regimens have been tried over the past three decades, including the recently concluded international immune tolerance induction study. However, the ideal regimen and the ideal candidate for successful tolerization are still debated even today.